Eshe Nelson

Eshe Nelson, an economics and business reporter for The New York Times based in London, dives into the transformation of GLP-1 drugs like Ozempic and Wegovy. She discusses the upcoming pricing changes that promise broader access, stemming from a significant agreement struck with pharmaceutical companies during the Trump administration. The conversation also covers how Ozempic evolved from a diabetes drug to a weight-loss sensation, and the ensuing supply challenges faced by its maker, Novo Nordisk, amid skyrocketing demand.

In this discussion, Professor Sir Tim Besley, a leading economist, Professor Richard Davies, an expert in economic theory, and Eshe Nelson, a financial journalist, dive into the pressing challenges of the British economy. They analyze the looming pressures on public finances and the differing party strategies regarding tax and spending cuts. The trio also discusses the implications of political instability, economic inequality, and the need for innovative policies to stimulate growth and investment. Future geopolitical dynamics and the role of strategic industries are critically examined.